Urinary Stone Treatment Devices And Equipment Global Market Report 2022

Major players in the urinary stone treatment devices (or) equipment market are Boston Scientific, Cook Medical, C.R. Bard, DirexGroup, Dornier MedTech, Bard Medical Division, Richard Wolf, Siemens Healthineers AG, Olympus Corporation, and Karl Storz.

The global urinary stone treatment devices and equipment market is expected to grow from $2.55 billion in 2021 to $2.79 billion in 2022 at a compound annual growth rate (CAGR) of 9.5%. The market is expected to grow to $3.8 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%.

The urinary stone treatment devices (or) equipment market consists of sales of urinary stone treatment devices and related services which are used in the treatment and management of stones formed in the kidneys and urinary tract.Stones are made of minerals in the urine that form crystals and grow into stones.

About 85% of the stones are made of calcium, and the remaining portion is composed of various substances including cysteine, uric acid, or struvite.

The main products in the urinary stone treatment devices (or) equipment are the extracorporeal shock wave lithotripsy devices, holmium laser devices, intracorporeal lithotripsy devices, stone retrieval devices, and ureteral stents.Holmium laser devices use pulsed laser and emit light at 2100 nm to break stones in the urinary tract.

The stone types involved are calcium stones, struvite, uric acid, cystine, and drug-induced. The various end-users are hospitals, ambulatory surgery centers, and others.

The increasing prevalence of Kidney Stones, especially in the geriatric population is driving the urinary stone treatment devices and equipment market growth.The incidence of urolithiasis is reported to be increasing across the globe.

According to a study, about 30% of people around the world are obese and nearly 900 million people are geriatrics which is expected to increase to 1.4 billion by 2030. The incidence of kidney stones is globally increasing with an estimated prevalence ranging up to 15%. According to a Robotic Stone survey, the probability of stone formation in Saudi Arabia is 20.1% and 13% in the USA. Stone diseases or urolithiasis are frequent in the aging population. Asia Pacific is presently home to more than half of the world’s aging population above 60 years and the number is expected to rise to 2.45 billion by 2050.

Lack of public awareness and proper knowledge about the problems associated with urinary stone diseases, particularly in under-developed countries acts as a major factor hindering market growth.This lack of proper knowledge becomes a roadblock for the Urinary stone treatment device manufacturers because of many cases being unnoticed/unaddressed which amounts to a decrease in demand for these devices.

For instance, according to a study conducted in Saudi Arabia, 44% of the participants had a family member suffering from urinary stone disease and 9.6% had urinary stones themselves, which suggests a high prevalence of the ailment in the country. But there was an incidence of lack of awareness and misconceptions among the people in most parts of that region.

Companies in the industry are investing in advanced laser technology and robot-assisted surgeries to treat urolithiasis.Urolithiasis is a disease condition where calculi or stones are formed in the kidney, bladder, and urinary tract of the human body.

Urolithiasis open surgeries are increasingly conducted with the help of minimally invasive procedures, advanced lasers, enhanced surgical tools, and robot-assisted devices to reduce hospitalization time, be less invasive and enable a shorter bladder catheterization time. For instance, Boston Scientific Co. is investing by way of an agreement with Lumenis, a company offering minimally-invasive clinical solutions, and holmium laser technology, to use and leverage the benefits of advanced laser technology.

In March 2019, regarding a field corrective action sent by Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for medical devices of the UK, C.R Bard, a subsidiary of Becton, Dickinson, and Company (BD) removed its Women’s Pelvic Organ Prolapse and Stress Urinary Incontinence Mesh devices from the European market. This initiative of ceasing production and distribution of these devices and removal of these products from hospitals and distribution centers was done to protect patient and user safety from these devices.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the urinary stone treatment devices (or) equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.